These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

914 related articles for article (PubMed ID: 16477396)

  • 81. Potential for airborne contamination in turbulent- and unidirectional-airflow compounding aseptic isolators.
    Peters GF; McKeon MR; Weiss WT
    Am J Health Syst Pharm; 2007 Mar; 64(6):622-31. PubMed ID: 17353571
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Implementing United States pharmacopeia chapter <1163> quality assurance in pharmaceutical compounding, part 2: documentation and verification.
    Allen LV
    Int J Pharm Compd; 2012; 16(3):230-4. PubMed ID: 23050301
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Disinfectants as an aid for good manufacturing practice in the pharmaceutical industry.
    Wallhäusser KH
    J Pharm Belg; 1981; 36(5):283-97. PubMed ID: 7310623
    [No Abstract]   [Full Text] [Related]  

  • 84. [Changes in the norms governing practices for the manufacture of pharmaceutical products: implications for the MERCOSUR].
    Temprano G; Prats S; Bregni C
    Boll Chim Farm; 1998 Nov; 137(10):426-38. PubMed ID: 9880947
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Drug product equivalence--the problem, the challenge, and the U.S.P.
    Macek TJ
    Am J Pharm Sci Support Public Health; 1971; 143(6):188-94. PubMed ID: 5140167
    [No Abstract]   [Full Text] [Related]  

  • 86. Dry-heat Depyrogenation Ovens for Pharmaceutical Compounding Facilities.
    Weller T; Kragseth R; Dullinger R; Illum H; Perry A
    Int J Pharm Compd; 2015; 19(3):182-92. PubMed ID: 26714359
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Control of drugs in foreign countries].
    Buriánek J; Parrák V
    Cesk Farm; 1973 Jul; 22(6):247-53. PubMed ID: 4732551
    [No Abstract]   [Full Text] [Related]  

  • 88. Sterility of extemporaneously compounded preservative-free injections.
    Levchuk JW
    Am J Hosp Pharm; 1991 Jan; 48(1):71-2. PubMed ID: 2053941
    [No Abstract]   [Full Text] [Related]  

  • 89. Adulteration of drugs and foods: compendial approaches to lowering risk.
    Abernethy DR; Sheehan C; Griffiths JC; Williams RL;
    Clin Pharmacol Ther; 2009 Apr; 85(4):444-7. PubMed ID: 18463621
    [No Abstract]   [Full Text] [Related]  

  • 90. Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 1.
    Martin M
    Int J Pharm Compd; 2018; 22(5):401-404. PubMed ID: 30384338
    [TBL] [Abstract][Full Text] [Related]  

  • 91. On the accountability problem of the pharmaceutical industry.
    Roberts CD
    Pharmazie; 1973 Jan; 28(1):49-51. PubMed ID: 4714241
    [No Abstract]   [Full Text] [Related]  

  • 92. Improving drug manufacturing with process analytical technology.
    Rodrigues LO; Alves TP; Cardoso JP; Menezes JC
    IDrugs; 2006 Jan; 9(1):44-8. PubMed ID: 16374733
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Drug counterfeiting and counter measures. Study by the Hungarian National Alliance Against Drug Counterfeiting].
    Psychiatr Hung; 2009; 24(3):205-14. PubMed ID: 20017282
    [No Abstract]   [Full Text] [Related]  

  • 94. International Conference on Harmonisation; guidance on Q9 Quality Risk Management; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jun; 71(106):32105-6. PubMed ID: 16795933
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Standards for particulate matter in all parenteral drug products.
    Jeffrey LP; Pinkus TF
    Am J Hosp Pharm; 1976 Sep; 33(9):879-80. PubMed ID: 984053
    [No Abstract]   [Full Text] [Related]  

  • 96. Global perspective on specifications for biotechnology products--perspective from Japan.
    Hayakawa T
    Dev Biol Stand; 1997; 91():15-23. PubMed ID: 9413678
    [No Abstract]   [Full Text] [Related]  

  • 97. Development of specifications for biotechnology products--perspective from Europe.
    Trouvin JH
    Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679
    [No Abstract]   [Full Text] [Related]  

  • 98. Retrospective view of the interfacial relationship of the pharmaceutical industry with the Food and Drug Administration and the United States Pharmacopeia.
    Hammer HF
    J Parenter Sci Technol; 1984; 38(4):159-63. PubMed ID: 6491859
    [No Abstract]   [Full Text] [Related]  

  • 99. Applying Quality by Design Concepts to Pharmacy Compounding.
    Timko RJ
    Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Biopharmaceutic equivalency and the role of the Food & Drug Administration.
    Hodges RM
    Am J Hosp Pharm; 1968 Mar; 25(3):121-7. PubMed ID: 5658859
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.